Drug class
Phenolic depigmenting agent; tyrosinase inhibitor
Mechanism of action
Inhibits melanogenesis through effects on tyrosinase and melanin synthesis, reducing pigment production in treated skin. It can cause local irritation and hypopigmentation; the effect is local and formulation-dependent.
General use cases
- Treatment of solar lentigines (sun-induced age spots) in adults when used in the authorised fixed combination with tretinoin; mequinol monotherapy should not be assigned that combination-product indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
